cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease (CAMPERR)

Overview

Información sobre este estudio

The purpose of this multicenter prospective observational case-control study is to train and validate Adela’s cfMeDIP-seq based methylome profiling platform to detect and differentiate multiple cancer subtypes. In addition, this study includes longitudinal follow-up for a subset of participants to train and validate the methylome profiling platform to detect minimal residual disease and recurrence.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Case Inclusion Criteria:

- Newly diagnosed (within 90 days) with cancer or a recurrence of a cancer diagnosed > 5 years ago of one of the following subtypes: Invasive Brain, Breast, Bladder, Cervical, Colorectal, Endometrial, Esophageal, Gastric, Head and Neck, Hepatobiliary, Lung, Ovarian,  Pancreatic, Prostate, Renal, Sarcoma, Thyroid; Leukemia, Lymphoma, Multiple Myeloma.

- Able and willing to provide informed consent.

- ≥ 40 years of age.

Case Exclusion Criteria:

- Currently receiving any treatment for cancer.

- Currently taking any demethylating agents/DNA hypomethylating agents.

- Simultaneously diagnosed with two or more invasive cancers.

- Diagnosed with any invasive or non-invasive cancer in addition to the index cancer in the last 5 years.

- Currently diagnosed with any chronic hematopoietic cancer (e.g., chronic CLL) in addition to the index cancer.

- Currently diagnosed with any myelodysplastic syndromes and/or precursor hematologic conditions (e.g., MGUS) in addition to the index cancer.

- Women who are known to be pregnant (self-reported).

Control Inclusion Criteria:

- Not diagnosed with any cancer in the last 5 years (non-invasive cancer is allowed).

- Able and willing to provide informed consent.

- ≥ 40 years of age.

Control Exclusion Criteria:

- Currently receiving any treatment for cancer.

- Currently taking any demethylating agents/DNA hypomethylating agents.

- Women who are known to be pregnant (self-reported).

Eligibility last updated 9/26/22. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Lisa Boardman, M.D.

Abierto para la inscripción

Contact information:

Angela Emanuel M.H.S.A.

(507) 293-0916

Emanuel.Angela@mayo.edu

More information

Publicaciones

Publications are currently not available

Información adicional de contacto

Formulario de contacto para ensayos sobre cáncer

Teléfono: 855-776-0015 (toll-free)

Preguntas de estudios clínicos para pacientes internacionales